Ameet Sarpatwari

Ameet Sarpatwari, PhD, JD

Faculty Member of the Center
Member, HMS Center for Bioethics

Ameet Sarpatwari is an Assistant Professor of Population Medicine at the Harvard Pilgrim Health Care Institute and Harvard Medical School. His research draws upon his interdisciplinary training as an epidemiologist and lawyer and focuses on the effects of laws and regulations on therapeutic development, approval, use, and related public health outcomes.

Dr. Sarpatwari's work has been highly influential. His writing and resulted in multiple invitations to testify before Congress and state legislatures, to discuss proposed legislation with Hill staffers, and to be approached routinely for insight on pharmaceutical policy by reporters from such prominent news sources as the New York Times, Washington Post, and NPR.

In addition to his primary position within the Institute's division of Health Policy and Insurance Research, Dr. Sarpatwari is also a faculty member in the Center for Bioethics at Harvard Medical School, the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health ("Harvard Chan School"), and the Harvard-MIT Center for Regulatory Science. At the Harvard Chan School, he serves as the Faculty Director of the JD/MPH program and teaches a highly acclaimed class on public health law.

Dr. Sarpatwari completed his undergraduate studies at the University of Virginia, where he was a Jefferson Scholar. He studied epidemiology at the University of Cambridge, where he received a Ph.D. He subsequently studied law at the University of Maryland as a John L. Thomas Leadership Scholar. Following his legal studies, he joined the Program On Regulation, Therapeutics, And Law (PORTAL) in the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital and Harvard Medical School as a post-doctoral fellow. He remained with PORTAL, serving as its Assistant Director for several years.

Publications View
Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug Makers.
Authors: Authors: Kesselheim AS, Rome BN, Sarpatwari A, Avorn J.
Health Aff (Millwood)
View full abstract on Pubmed
The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
Authors: Authors: Wang B, Studdert DM, Sarpatwari A, Franklin JM, Landon J, Kesselheim AS.
PLoS One
View full abstract on Pubmed
Factors Influencing Prescription Drug Costs in the United States-Reply.
Authors: Authors: Sarpatwari A, Avorn J, Kesselheim AS.
JAMA
View full abstract on Pubmed
The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
Authors: Authors: Kesselheim AS, Avorn J, Sarpatwari A.
JAMA
View full abstract on Pubmed
Balancing benefits and harms: privacy protection policies.
Authors: Authors: Sarpatwari A, Gagne JJ.
Pharmacoepidemiol Drug Saf
View full abstract on Pubmed
Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Authors: Authors: Yeh JS, Sarpatwari A, Kesselheim AS.
Drug Saf
View full abstract on Pubmed
Navigating the Dermatological Drug Cost Curve.
Authors: Authors: Sarpatwari A, Kesselheim AS.
JAMA
View full abstract on Pubmed
State Initiatives to Control Medication Costs--Can Transparency Legislation Help?
Authors: Authors: Sarpatwari A, Avorn J, Kesselheim AS.
N Engl J Med
View full abstract on Pubmed
Efficacy of the Priority Review Voucher Program.
Authors: Authors: Sarpatwari A, Kesselheim AS.
JAMA
View full abstract on Pubmed
The Case for Reforming Drug Naming: Should Brand Name Trademark Protections Expire upon Generic Entry?
Authors: Authors: Sarpatwari A, Kesselheim AS.
PLoS Med
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
General Medicine-OBC-3030, N2
1620 Tremont St
Boston, MA 02120